お知らせ • May 12
Santen Pharmaceutical Co., Ltd., Annual General Meeting, Jun 23, 2026 Santen Pharmaceutical Co., Ltd., Annual General Meeting, Jun 23, 2026. お知らせ • May 09
Santen Pharmaceutical Co., Ltd. to Report Fiscal Year 2026 Results on May 12, 2026 Santen Pharmaceutical Co., Ltd. announced that they will report fiscal year 2026 results on May 12, 2026 お知らせ • Jan 08
RVL Pharmaceuticals Announces Santen Obtains Manufacturing and Marketing Approval in Japan for UPNEEQ ®? Mini Ophthalmic Solution 0.1% RVL Pharmaceuticals Inc. and its affiliates announced Santen Pharmaceutical Co., Ltd. ("Santen"), a leading ophthalmology company has obtained the manufacturing and marketing approval in Japan for UPNEEQ®? Mini Ophthalmic Solution 0.1% (generic name:oxymetazoline hydrochloride; development code: STN1013800; hereinafter the product), a treatment for acquired blepharoptosis (low-lying eyelids). This milestone expands access in Japan to the first approved non-invasive treatment for blepharoptosis, where treatment options have primarily been limited to surgical procedures. In the U.S. market, Upneeq®? is the first and only FDA-approved prescription eye drop for acquired blepharoptOS (low-lying eyelids), and continues to demonstrate strong patient satisfaction, increased adoption, and channel diversification. The superiority of the product was demonstrated in the primary endpoint - a change from baseline at 2 hours after administration in MRD-1 (Marginal Reflex Distance-1, the margin between the upper eyelid and the center of the pupil) at Day 14 after the start of treatment--in the once-daily group versus the placebo eye drop group. In addition, an exploratory analysis showed that improvement in MRD-1 persisted for more than 8 hours after instillation. No serious adverse effects or adverse effects leading to treatment discontinuation were observed during the study. In the Phase 3 clinical trial in Japan (once-daily instillation for 6 months), no trend toward strengthening of the eyelid-lifting effect or rebound effect was observed. In this clinical study, MRD-1 was defined as the distance from the center of the pupil to the upper eyelid margin, as determined from anterior segment photographs. Upneeq®? (oxymetazoline hydrochlorides ophthalmic solution), 0.1% is a prescription eyedrop used to treat acquired blepharoptosis ("low-lying lids") in adults. The product was approved in the US by the FDA in July 2020. Low-lying lids may be related to conditions such as stroke and/or brain aneurysm, Horner syndrome, myasthenia gravis, loss of the ability to move eye muscles, eye infection and eye tumors. Tell your doctor if you have any of these conditions. UPNEEQ is a type of medication that may affect blood pressure. Upneeq®? activates a muscle in the eyelids, lifting the lid for a more open and awake look. One drop daily is clinically proven to provide visible results in as fast as 5 minutes and lasts up to 8 hours. In July 2020, Osmotica Pharmaceuticals plc (due to a company name change, currently known as RVL Pharmaceuticals Inc.), entered into an exclusive license agreement with Santen, covering the continued development, registration, and commercialization rights for RVL-1201, a 0.1% oxymetazoline hydrochloride ophthalmic solution, in Japan and certain other international markets. Santen has been developing the product as STN1013800. お知らせ • Dec 02
Santen Pharmaceutical Co., Ltd. to Report Q3, 2026 Results on Feb 05, 2026 Santen Pharmaceutical Co., Ltd. announced that they will report Q3, 2026 results on Feb 05, 2026 お知らせ • Nov 07
Santen Pharmaceutical Co., Ltd. Receives UK Approval for Ryjunea®? (Low-Dose Atropine 0.1 Mg/L) to Slow Progression of Childhood Myopia Santen announced that the UK Medicines and Healthcare products Regulatory Agency (MHRA) has approved Ryjunea®? (low-dose atropine 0.1 mg/ml), the first licensed treatment in the UK to slow the progression of myopia in children. The approval follows the European Commission authorisation and the first launch in Germany earlier this year, with additional launches in Europe to follow. Short-sightedness is rising fast among children in the UK, where many children now live with myopia, more than double the number from 50 years ago. Increased screen time, less outdoor activity, and intensive near work are putting a growing strain on young eyes. Globally, approximately one in three children and adolescents are expected to be affected by 2050. The first signs of myopia often appear in daily life: a child squinting to read the board, moving closer to the TV, or struggling to recognise faces at a distance. Myopia can affect learning, confidence, and participation in school and play. Early interventions are key to slowing progression and supporting children's eye health and wellbeing. Childhood myopia increases the risk of severe eye disease later in life. "A comprehensive approach, combining lifestyle habits, optical correction, and approved medical options, gives children the best chance to support healthy vision into adulthood." With over 135 years of experience in eye health, Santen is committed to advancing early intervention and collaboration in paediatric myopia, for happier lives and brighter futures. Ryjunea®? is a registered trademark of Santen Pharmaceutical Co., Ltd. Ryjunea®®? is indicated for slowing the progression of myopia in paediatric patients. Treatment may be initiated in children aged 3-14 years with a progression rate of 0.5 D or more per year and a severity of -0.5 D to -6.0 D. It is backed by the Phase III STAR study, showing that Ryjunea®? significantly reduced the annual progression of myopia with an acceptable safety and tolerability profile. As a low-dose atropine eye drop, administered once daily at bedtime, it provides a convenient way to manage myopia that integrates easily into a child's routine. The product is licensed from Sydnexis Inc. to Santen's Switzerland-based affiliate, Santen SA, for registration and commercialisation across Europe, the Middle East, and Africa (EMEA). It has received market authorisation from the European Commission on June 2, and now from the UK Medicines and Healthcare Products Regulatory Agency (MHRA) on October 30. お知らせ • Sep 01
Santen Pharmaceutical Co., Ltd. to Report Q2, 2026 Results on Nov 06, 2025 Santen Pharmaceutical Co., Ltd. announced that they will report Q2, 2026 results on Nov 06, 2025 お知らせ • Jun 06
Santen Pharmaceutical Co., Ltd. to Report Q1, 2026 Results on Aug 07, 2025 Santen Pharmaceutical Co., Ltd. announced that they will report Q1, 2026 results on Aug 07, 2025 お知らせ • May 15
Santen Pharmaceutical Co., Ltd. (TSE:4536) announces an Equity Buyback for 19,800,000 shares, representing 5.8% for ¥35,000 million. Santen Pharmaceutical Co., Ltd. (TSE:4536) announces a share repurchase program. Under the program, the company will repurchase up to 19,800,000 of its common shares, representing 5.8% of its outstanding shares for ¥35,000 million. The program is aimed at enhancing shareholder returns and further improving capital efficiency. The plan will be valid up to November 5, 2025. As on November 5, 2025, the company had 341,423,368 shares outstanding and 632,186 shares in its treasury. お知らせ • May 14
Santen Pharmaceutical Co., Ltd., Annual General Meeting, Jun 24, 2025 Santen Pharmaceutical Co., Ltd., Annual General Meeting, Jun 24, 2025. お知らせ • Mar 06
Santen Pharmaceutical Co., Ltd. to Report Fiscal Year 2025 Results on May 13, 2025 Santen Pharmaceutical Co., Ltd. announced that they will report fiscal year 2025 results on May 13, 2025 お知らせ • Dec 03
Santen Pharmaceutical Co., Ltd. to Report Q3, 2025 Results on Feb 06, 2025 Santen Pharmaceutical Co., Ltd. announced that they will report Q3, 2025 results on Feb 06, 2025 お知らせ • Nov 07
Santen Pharmaceutical Co., Ltd. (TSE:4536) announces an Equity Buyback for 5,000,000 shares, representing 1.44% for ¥10,000 million. Santen Pharmaceutical Co., Ltd. (TSE:4536) announces a share repurchase program. Under the program, the company will repurchase up to 5,000,000 of its common shares, representing 1.44% of its outstanding shares for ¥10,000 million. The purpose of the program is to enhance capital efficiency and improve return of profits based on a comprehensive consideration of factors such as profitability improvement and business environment in accordance with the capital allocation policy in the medium-term management plan. The repurchased shares will be cancelled. The plan will be valid up to March 21, 2025. As on October 31, 2024, the company had 347,002,868 shares outstanding and 17,019,386 shares in its treasury. お知らせ • Sep 04
Santen Pharmaceutical Co., Ltd. to Report Q2, 2025 Results on Nov 07, 2024 Santen Pharmaceutical Co., Ltd. announced that they will report Q2, 2025 results on Nov 07, 2024 お知らせ • Jun 02
Santen Pharmaceutical Co., Ltd. to Report Q1, 2025 Results on Aug 06, 2024 Santen Pharmaceutical Co., Ltd. announced that they will report Q1, 2025 results on Aug 06, 2024 お知らせ • May 11
Santen Pharmaceutical Co., Ltd., Annual General Meeting, Jun 25, 2024 Santen Pharmaceutical Co., Ltd., Annual General Meeting, Jun 25, 2024. お知らせ • Mar 02
Santen Pharmaceutical Co., Ltd. to Report Fiscal Year 2024 Results on May 09, 2024 Santen Pharmaceutical Co., Ltd. announced that they will report fiscal year 2024 results on May 09, 2024 お知らせ • Feb 09
Santen Pharmaceutical Co., Ltd. Revises Dividend Guidance for the Fiscal Year Ending March 31, 2024 Santen Pharmaceutical Co., Ltd. Revised Dividend guidance for the Fiscal Year Ending March 31, 2024. For the year, the company expects dividend of JPY 17.00 per share against previous guidance of JPY 16.00 per share. お知らせ • Dec 02
Santen Pharmaceutical Co., Ltd. to Report Q3, 2024 Results on Feb 08, 2024 Santen Pharmaceutical Co., Ltd. announced that they will report Q3, 2024 results on Feb 08, 2024 お知らせ • Sep 21
Santen Pharmaceutical Co., Ltd. Revises Consolidated Earnings Forecasts for the Fiscal Year Ending March 31, 2024 Santen Pharmaceutical Co., Ltd. revised consolidated earnings forecasts for the fiscal year ending March 31, 2024. For the year, on a core basis, the company expects revenue of ¥285,000 million, core operating profit of ¥50,000 million, core net profit for the year of ¥37,500 million and basic core earnings per share of ¥102.47 compared to the previous guidance of revenue of ¥273,000 million, core operating profit of ¥46,000 million, core net profit for the year of ¥34,500 million and basic core earnings per share of ¥94.27 provided earlier. On IFRS basis, the company expects revenue of ¥285,000 million, operating profit of ¥35,000 million, net profit for the year of ¥25,000 million and basic earnings per share of ¥68.34 compared to the previous guidance of revenue of ¥273,000 million, operating profit of ¥32,000 million, core net profit for the year of ¥22,400 million and basic core earnings per share of ¥61.24 provided earlier. お知らせ • Aug 27
Santen Pharmaceutical Co., Ltd. to Report Q2, 2024 Results on Nov 07, 2023 Santen Pharmaceutical Co., Ltd. announced that they will report Q2, 2024 results on Nov 07, 2023 お知らせ • May 31
Santen Pharmaceutical Co., Ltd. to Report Q1, 2024 Results on Aug 03, 2023 Santen Pharmaceutical Co., Ltd. announced that they will report Q1, 2024 results on Aug 03, 2023 お知らせ • Feb 08
Santen Pharmaceutical Co., Ltd. Revises Consolidated and Core Earnings Guidance for the Year Ending March 31, 2023 Santen Pharmaceutical Co., Ltd. revised consolidated and core earnings guidance for the year ending March 31, 2023. For the year on consolidated basis, the company revised revenue of JPY 272,000 million compared to previous guidance of JPY 280,000 million. Operating loss of JPY 6,500 million compared to previous guidance operating profit of JPY 4,000 million. Net loss for the year of JPY 15,500 million compared to previous guidance of JPY 5,500 million. Basic loss per share of JPY 40.01 compared to previous guidance of JPY 14.20.For the year on core basis, the company revised revenue of JPY 272,000 million compared to previous guidance of JPY 280,000 million. Core operating profit of JPY 41,000 million compared to previous guidance JPY 45,500 million. Core Net profit for the year of JPY 30,800 million compared to previous guidance of JPY 34,100 million. Core Basic earnings per share of JPY 79.50 compared to previous guidance of JPY 88.04. お知らせ • Dec 18
Santen Pharmaceutical Co., Ltd. to Report Q3, 2023 Results on Feb 07, 2023 Santen Pharmaceutical Co., Ltd. announced that they will report Q3, 2023 results on Feb 07, 2023 お知らせ • May 12
Santen Pharmaceutical Co., Ltd., Annual General Meeting, Jun 27, 2023 Santen Pharmaceutical Co., Ltd., Annual General Meeting, Jun 27, 2023.